Journal
DRUG DISCOVERY TODAY
Volume 19, Issue 12, Pages 1928-1935Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2014.08.004
Keywords
-
Categories
Funding
- Catholic University of the Sacred Heart, Fondi di Ateneo
Ask authors/readers for more resources
Chronic obstructive pulmonary disease (COPD) is characterized by large phenotype variability, reflected by a highly variable response to pharmacological treatment. Nevertheless, current guidelines suggest that patients with COPD of similar severity should be treated in the same way. The phenotype-based pharmacotherapeutic approach proposes bronchodilators alone in the nonfrequent exacerbator phenotype and a combination of bronchodilators and inhaled corticosteroids in patients with asthma COPD overlap syndrome (ACOS) and moderate-to-severe exacerbator phenotype. The clinical importance of phenotypes is changing the paradigm of COPD management from evidence-based to personalized medicine. However, the personalized pharmacological strategy of COPD has to be validated in future clinical studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available